Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer

NCT01256762 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT01256762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01256762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study Of Imetelstat (GRN163L) In Combination With Paclitaxel (With Or Without Bevacizumab) in Patients With Locally Recurrent Or Metastatic Breast Cancer
Lead sponsor
Geron Corporation
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
December 31, 2012
Enrollment
166 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

locally recurrent or metastatic breast cancer